title: Cisplatin-based therapy: a neurological and neuropsychological review.
abstract: The present paper reviews research in the area of the broad-spectrum chemotherapeutic agent cisplatin (cis-diamminedichloro-platinum II) and examines the implications for clinical neuropsychology arising from the neurological disruption associated with cisplatin-based therapy. The paper begins with a brief review of cisplatin treatment in terms other than survival alone, and examines the side-effects and the potential central nervous system (CNS) dysfunction in terms of neurological symptoms and concomitant implications for neuropsychology. Two main implications for clinical neuropsychology arising from cisplatin therapy are identified. First, cisplatin therapy impacts upon the psychological well-being of the patient, particularly during and in the months following treatment. It is suggested that during this time, a primary role for neuropsychology is to focus upon the monitoring and the active enhancement of the patient's social, psychological and spiritual resources. Second, with regard to neurocognitive changes, the review suggests that (1) neurocognitive assessment may not yield stable results within 8 months following treatment and (2) while perceptual, memory, attentional and executive dysfunction may be predicted following cisplatin treatment, little systematic research has been carried out to investigate such a possibility. Future research might profitably address this issue and also specifically examine the effects of low dosage cisplatin-based therapy and the effects of recently developed neuroprotective agents. Finally, there is some evidence to suggest that women may be more susceptible to neurotoxicity during cisplatin therapy, but no gender-related cognitive effects are reported in the cisplatin literature. Future research could usefully investigate gender differences in association with cisplatin chemotherapy.
authors.affiliation: School of Psychology, University of Queensland, Brisbane, Queensland, Australia.
authors.forename: L
authors.initials: L
authors.lastname: Troy
authors.forename: K
authors.initials: K
authors.lastname: McFarland
authors.forename: S
authors.initials: S
authors.lastname: Littman-Power
authors.forename: B J
authors.initials: BJ
authors.lastname: Kelly
authors.forename: E T
authors.initials: ET
authors.lastname: Walpole
authors.forename: D
authors.initials: D
authors.lastname: Wyld
authors.forename: D
authors.initials: D
authors.lastname: Thomson
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000523:psychology; D009422:Nervous System Diseases / Q000139:chemically induced* / Q000175:diagnosis; D009460:Neurologic Examination / Q000187:drug effects; D009483:Neuropsychological Tests; D019966:Substance-Related Disorders / Q000175:diagnosis / Q000209:etiology*
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin